Malignant Hepatocellular Neoplasm, not Otherwise Specified, Displays Poorer Chemoresponsiveness and Postoperative Prognosis than Hepatoblastoma
Cancer Research and Treatment · 2025
DOI: 10.4143/crt.2025.117 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Cancer Research and Treatment, 2025. Verfasst von In Hye Song und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Liver Neoplasms, Hepatoblastoma, Carcinoma, Hepatocellular. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Asan Institute for Life Sciences, Asan Medical Center.
Abstract (Originalsprache)
PURPOSE: Malignant hepatocellular neoplasm, not otherwise specified (HCN-NOS) is a provisional diagnostic entity, characterised by intermediate or a combination of hepatoblastoma and pediatric hepatocellular carcinoma (p-HCC) features. We compared the characteristics of HCN-NOS with hepatoblastoma and p-HCC. MATERIALS AND METHODS: The records of 148 pediatric patients diagnosed with hepatocellular malignancy after resection were retrieved from the institutional database. Clinical parameters and histopathology slides were reviewed to re-establish each patient's diagnosis. Molecular analyses were conducted in 37 patients. RESULTS: Patients were profiled as 21 (14.2%) with HCN-NOS, 109 (73.6%) with hepatoblastoma, and 18 (12.2%) with p-HCC. The median age was 8.6 years in HCN-NOS, 1.2 years in hepatoblastoma, and 7.9 years in p-HCC. Background liver disease was frequently observed in p-HCC (11/18, 61%) but infrequent in HCN-NOS (4/21, 19%) and hepatoblastoma (4/109, 3.7%). HCN-NOS presented with a more advanced PRETEXT stage (p=0.012), metastasis (p < 0.001), and lymphovascular invasion (p < 0.001) than hepatoblastoma and p-HCC. Patients with HCN-NOS received longer cycles of preoperative chemotherapy; however, they reported a lower decrease in serum alpha-fetoprotein and tumor size than hepatoblastoma (p=0.043, p=0.004, and p=0.044, respectively). HCN-NOS was an independent poor prognostic factor for event-free survival (hazard ratio, 4.968; 95% confidence interval, 2.004 to 12.32; p < 0.001). CONCLUSION: The possibility of HCN-NOS should be considered in pediatric patients with liver cancer, especially those ≥ 5 years old with no background liver disease. Because HCN-NOS exhibits poor chemoresponsiveness and unfavourable postoperative prognosis, liver transplantation should be strongly considered.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- Department of Pediatric Surgery, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Korea.
- Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- Division of Pediatric Hematology/Oncology, Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Korea.
Förderung
- Asan Institute for Life Sciences, Asan Medical Center
Zitieren
APA
Song, I. H., Gang, S., Yoon, H. M., Kim, P. H., Ahn, B., Kim, J., Kim, D. H., Namgoong, J. M., & Koh, K. N. (2025). Malignant Hepatocellular Neoplasm, not Otherwise Specified, Displays Poorer Chemoresponsiveness and Postoperative Prognosis than Hepatoblastoma. Cancer Research and Treatment. https://doi.org/10.4143/crt.2025.117
Vancouver
Song IH, Gang S, Yoon HM, Kim PH, Ahn B, Kim J, et al. Malignant Hepatocellular Neoplasm, not Otherwise Specified, Displays Poorer Chemoresponsiveness and Postoperative Prognosis than Hepatoblastoma. Cancer Research and Treatment. 2025. doi:10.4143/crt.2025.117
BibTeX
@article{Song2025,
author = {Song, In Hye and Gang, Sujin and Yoon, Hee Mang and Kim, Pyeong Hwa and Ahn, Bokyung and Kim, Jihun and Kim, Deok Hoon and Namgoong, Jung-Man and Koh, Kyung-Nam},
title = {Malignant Hepatocellular Neoplasm, not Otherwise Specified, Displays Poorer Chemoresponsiveness and Postoperative Prognosis than Hepatoblastoma},
journal = {Cancer Research and Treatment},
year = {2025},
doi = {10.4143/crt.2025.117}
}
EUVIMED